Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |3 July 2001

A New Anti-Inflammatory Therapy (Infliximab) for Complicated Sarcoidosis

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information

  • The summary below is from the full report titled “Treatment of Complicated Sarcoidosis with Infliximab Anti–Tumor Necrosis Factor-α Therapy.” It is in the 3 July 2001 issue of Annals of Internal Medicine (volume 135, pages 27-31). The authors are AMF Yee and MB Pochapin.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done and what did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

What is the problem and what is known about it so far?

Sarcoidosis is a disease of unknown cause that produces chronic inflammation in many different organs of the body. The disease can appear in several ways, but it most often damages the lungs. Tissue samples from patients with sarcoidosis show a typical appearance under a microscope. Although mild cases of the disease frequently get better without treatment, severe cases often require treatment with corticosteroid medications. Inflammation in sarcoidosis involves the accumulation of tiny collections of cells (known as noncaseating granulomas) throughout the affected tissue. One of the cell types in these granulomas is known as a macrophage. Macrophages produce a chemical called tumor necrosis factor-α (TNF-α) that may accelerate the inflammatory process. Corticosteroids decrease the production of TNF-α. Unfortunately, corticosteroid treatment does not always work and may have many toxic side effects. Alternative treatments for sarcoidosis would therefore be very helpful. A new pharmaceutical agent, infliximab, is a human-made antibody (antibodies are substances that the body usually uses to fight off infection) that specifically blocks the effect of TNF-α.

Why did the researchers do this particular study?

The researchers wanted to see if infliximab could be used effectively to treat a patient with sarcoidosis who did not respond to corticosteroids.

Who was studied?

A 72-year-old woman with severe diarrhea, nodules in her lungs, enlarged lymph nodes, and abnormalities in her muscles. The patient underwent biopsies, and the tissue samples showed changes in tissue appearance that are typical of sarcoidosis. Despite corticosteroid therapy, the patient's illness got worse.

How was the study done and what did the researchers find?

Nine months after the onset of her illness, after corticosteroids had failed to produce improvement, the patient was given a dose of infliximab. Within 2 days, the woman's muscle strength increased, and within 1 week, her diarrhea improved; the lung nodules went away completely. However, after the third dose of infliximab, abnormal blood clots formed. Although it was unclear whether infliximab contributed to this complication, the therapy was discontinued. Soon afterward, soft bowel movements returned. The patient then received another drug (thalidomide) that relieved her symptoms.

What were the limitations of the study?

Only one patient was studied, and she did not have the typical clinical pattern of sarcoidosis (which usually affects the lung more than the bowel). Infliximab seems to have worked through its action against TNF-α; however, the authors cannot be certain of this.

What are the implications of the study?

Infliximab may be useful in treating sarcoidosis that does not respond to corticosteroid therapy.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

A New Anti-Inflammatory Therapy (Infliximab) for Complicated Sarcoidosis. Ann Intern Med. 2001;135:I–20. doi: https://doi.org/10.7326/0003-4819-135-1-200107030-00009

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2020

×
Permissions

Published: Ann Intern Med. 2001;135(1):I-20.

DOI: 10.7326/0003-4819-135-1-200107030-00009

©
2001 American College of Physicians
0 Citations
Advertisement

See Also
Treatment of Complicated Sarcoidosis with Infliximab Anti–Tumor Necrosis Factor-α Therapy
View MoreView Less

Related Articles
Treatment of Complicated Sarcoidosis with Infliximab Anti–Tumor Necrosis Factor-α Therapy
Annals of Internal Medicine; 135 (1): 27-31
Nonsteroidal Anti-inflammatory Drug Treatment for Postoperative Pericardial Effusion: A Multicenter Randomized, Double-Blind Trial
Annals of Internal Medicine; 152 (3): 137-143
Asymptomatic Postoperative Pericardial Effusions: Against the Routine Use of Anti-inflammatory Drug Therapy
Annals of Internal Medicine; 152 (3): 186-187
Treating Postoperative Pericardial Effusion With Nonsteroidal Anti-inflammatory Drug Therapy
Annals of Internal Medicine; 152 (3): I-32
View MoreView Less

Journal Club
Review: Azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn disease
Annals of Internal Medicine; 148 (12): JC4-9
View MoreView Less

Related Point of Care
Sarcoidosis
Annals of Internal Medicine; 156 (9): ITC5-1
View MoreView Less

Related Topics
Diarrhea
Endocrine and Metabolism
Gastroenterology/Hepatology
Pulmonary/Critical Care

Diarrhea, Endocrine and Metabolism, Gastroenterology/Hepatology, Pulmonary/Critical Care.

PubMed Articles
Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany.
Dig Dis 2020.
Pharmacokinetics, Pharmacodynamics and Immunogenicity of Infliximab in Paediatric Inflammatory Bowel Disease; a Systematic Review and Revised Dosing Considerations.
J Pediatr Gastroenterol Nutr 2020.
View More

Results provided by: PubMed

Advertisement
CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2020 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×